Hepatitis D in Kyrgyzstan. The patient community is advocating for a separate treatment program.

A group of representatives from the Eurasian Community for Access to Treatment (ECAT) has sent an official letter to the Minister of Health of Kyrgyzstan with proposals for improving the regulatory and programmatic framework in the field of diagnosis and therapy for hepatitis delta virus (HDV). Details can be found on the organization's website.

In the letter, it is emphasized that by the end of 2025, a new drug for the treatment of delta hepatitis, bulvertid, was introduced in the country. However, the diagnosis and therapy of HDV are still conducted under a clinical protocol designed for hepatitis B.

ECAT members express concern that the lack of specific clinical recommendations and program documents for delta hepatitis diminishes the significance of this disease and complicates the acquisition of systemic funding and planning for patient assistance.

The appeal also cites data from the Republican Center for the Control of Hematogenous Viral Hepatitis and HIV, indicating that as of September 1, 2025, 17% of patients with hepatitis B (3,120 individuals) were found to have co-infection with delta hepatitis.

In this regard, ECAT representatives request the Ministry of Health to take two main steps:

to create a working group involving representatives of the patient community to develop and implement a national program for delta hepatitis with separate funding,
to develop and approve clinical recommendations for HDV as an independent nosology.

ECAT believes that the preparation and adaptation of the regulatory framework is of particular importance for the further development of delta hepatitis therapy: in addition to bulvertid, several companies are currently conducting clinical trials of other treatment methods, and pre-established mechanisms will facilitate the rapid introduction of new drugs and ensure more stable access for patients to diagnosis and therapy.

The image on the main page is illustrative: gemotest.ru.

Read also:

Doctors discussed the transmission routes and treatment of hepatitis B and D at a seminar in Bishkek